We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
bluebird bio (BLUE) Looks Good: Stock Adds 11% in Session
Read MoreHide Full Article
bluebird bio, Inc. (BLUE - Free Report) was a big mover last session, as the company saw its shares rise nearly 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 40% in the past one-month time frame.
The stock gained after some analysts raised the target price of the company. The upgrade was based on increased chances of obtaining approval for bluebird bio’s CAR-T bb2121, a cancer treatment drug, because of Kymriah’s recent approval from FDA.
The company has seen five negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
bluebird bio currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Is BLUE going up? Or down? Predict to see what others think: Up or Down
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
bluebird bio (BLUE) Looks Good: Stock Adds 11% in Session
bluebird bio, Inc. (BLUE - Free Report) was a big mover last session, as the company saw its shares rise nearly 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 40% in the past one-month time frame.
The stock gained after some analysts raised the target price of the company. The upgrade was based on increased chances of obtaining approval for bluebird bio’s CAR-T bb2121, a cancer treatment drug, because of Kymriah’s recent approval from FDA.
The company has seen five negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
bluebird bio currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
bluebird bio, Inc. Price
bluebird bio, Inc. Price | bluebird bio, Inc. Quote
Investors interested in the Medical - Biomedical and Genetics may consider a better-ranked stock like Vanda Pharmaceuticals Inc. (VNDA - Free Report) , which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is BLUE going up? Or down? Predict to see what others think: Up or Down
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>